Genetic Characterization of Brain Metastases in the Era of Targeted Therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2017-09-25
DOI
10.3389/fonc.2017.00230
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DNA Repair in Prostate Cancer: Biology and Clinical Implications
- (2017) Joaquin Mateo et al. EUROPEAN UROLOGY
- Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations
- (2017) S. Balendran et al. JOURNAL OF NEURO-ONCOLOGY
- Treatment of brain metastases in the modern genomic era
- (2017) Ibiayi Dagogo-Jack et al. PHARMACOLOGY & THERAPEUTICS
- Clinical Discussion and Review of the Management of Brain Metastases
- (2017) Priscilla K. Brastianos et al. Journal of the National Comprehensive Cancer Network
- Systematic review: brain metastases from colorectal cancer—Incidence and patient characteristics
- (2016) Troels Dreier Christensen et al. BMC CANCER
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
- (2016) P. Ballard et al. CLINICAL CANCER RESEARCH
- Targeted Therapies for Brain Metastases from Breast Cancer
- (2016) Vyshak Venur et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid
- (2016) Elena I. Pentsova et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
- (2016) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- (2016) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
- (2016) Martin Schuler et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- (2016) Alice T Shaw et al. LANCET ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- EGFR mutation status on brain metastases from non-small cell lung cancer
- (2016) Fred Hsu et al. LUNG CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
- (2015) M E Gore et al. BRITISH JOURNAL OF CANCER
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
- (2015) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study
- (2015) D. Jäger et al. Clinical Genitourinary Cancer
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer Prognosis Before and After Recurrence in a Population-Based Setting
- (2015) Dario Consonni et al. JNCI-Journal of the National Cancer Institute
- Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
- (2015) Petra Hoffknecht et al. Journal of Thoracic Oncology
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
- (2015) Deepa Rangachari et al. LUNG CANCER
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis
- (2015) Q. Shen et al. ONCOLOGIST
- A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
- (2015) J. J. Harding et al. ONCOLOGIST
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
- (2015) Leticia De Mattos-Arruda et al. Nature Communications
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases
- (2015) P. K. Paik et al. Cancer Discovery
- The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain
- (2015) Rajendra P. Pangeni et al. Clinical Epigenetics
- Lung Cancer Prognosis Before and After Recurrence in a Population-Based Setting
- (2015) Dario Consonni et al. JNCI-Journal of the National Cancer Institute
- Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues
- (2014) Anna Sophie Berghoff et al. ACTA NEUROPATHOLOGICA
- Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
- (2014) S. M. Swain et al. ANNALS OF ONCOLOGY
- Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis
- (2014) Naoki Niikura et al. BREAST CANCER RESEARCH AND TREATMENT
- RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer
- (2014) Rona Yaeger et al. CANCER
- Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
- (2014) G. Chen et al. CLINICAL CANCER RESEARCH
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report†
- (2014) Jack M. Su et al. NEURO-ONCOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Genomic Analysis of Primary and Synchronous Metastatic Colorectal Cancers
- (2014) Sun Young Lee et al. PLoS One
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases
- (2013) Zhengbo Song et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma
- (2012) Jonathan Verma et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)
- (2012) Y.- L. Wu et al. ANNALS OF ONCOLOGY
- Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
- (2012) Nils D. Arvold et al. BREAST CANCER RESEARCH AND TREATMENT
- CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary
- (2012) C. Bachmann et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
- (2012) Thomas Bachelot et al. LANCET ONCOLOGY
- Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
- (2012) S.J. Park et al. LUNG CANCER
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
- (2011) M. Bianchi et al. ANNALS OF ONCOLOGY
- Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
- (2011) J. Beck et al. ANNALS OF ONCOLOGY
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
- (2011) J. Tie et al. CLINICAL CANCER RESEARCH
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
- (2011) Naoki Niikura et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
- (2011) Martin D. Forster et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
- (2011) Kunal S. Taskar et al. PHARMACEUTICAL RESEARCH
- Epidemiology of Brain Metastases
- (2011) Lakshmi Nayak et al. Current Oncology Reports
- Factors associated with the development of brain metastases
- (2010) Jessica L. Hubbs et al. CANCER
- Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
- (2010) P. R. Lockman et al. CLINICAL CANCER RESEARCH
- Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
- (2010) R. Porta et al. EUROPEAN RESPIRATORY JOURNAL
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2008) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
- (2008) J. D. Wolchok et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started